GLP-1 Medications: The Complete 2026 Guide to Semaglutide, Tirzepatide & More

What Are GLP-1 Receptor Agonists?

Definition: GLP-1 receptor agonists are a class of prescription medications that mimic glucagon-like peptide-1 (GLP-1), a gut-derived hormone released after eating. By binding to GLP-1 receptors in the brain, gut, and pancreas, they reduce appetite, slow stomach emptying, and improve blood sugar regulation—producing clinically meaningful weight loss.

GLP-1 (glucagon-like peptide-1) is an incretin hormone your intestines secrete within minutes of eating. In healthy individuals, it signals the hypothalamus to reduce hunger, prompts the pancreas to release insulin proportional to blood glucose, and slows the rate at which food leaves the stomach. The problem: natural GLP-1 has a half-life of just 1–2 minutes before enzymes break it down.

GLP-1 receptor agonist medications are engineered analogs of this hormone with dramatically extended half-lives—ranging from hours (liraglutide, dosed daily) to a full week (semaglutide, tirzepatide). This sustained receptor activation produces appetite suppression and metabolic effects far more powerful than the body's own hormone, which is why clinical trials show weight loss results that previously required bariatric surgery.

The class originated in diabetes care—liraglutide received its first FDA approval in 2010. Over the following decade, pharmaceutical innovation produced progressively more potent and convenient agents. Today, semaglutide and tirzepatide represent the standard of care for pharmacological obesity treatment, with a new generation of oral and multi-agonist drugs in late-stage development.

How GLP-1 Medications Work: Four Mechanisms

GLP-1 medications produce weight loss through four simultaneous physiological pathways. Understanding each mechanism explains both why the medications are so effective and why certain side effects occur:

Central appetite suppression

GLP-1 receptors in the hypothalamus and brainstem—brain regions that govern hunger, satiety, and reward—are directly activated. Patients consistently describe a dramatic quieting of "food noise": the constant mental preoccupation with food that characterizes obesity. Hunger signals become easier to override; highly palatable foods lose their urgency.

Delayed gastric emptying

Slowing the rate at which food exits the stomach extends post-meal fullness, allowing patients to feel satisfied with significantly smaller portions. This mechanism is also responsible for the nausea common during dose escalation—food sits in the stomach longer than the body is accustomed to, particularly after fatty or large meals.

Glucose-dependent insulin secretion

GLP-1 stimulates pancreatic beta cells to release insulin only when blood glucose is elevated, improving glycemic control without causing hypoglycemia. For patients with type 2 diabetes or prediabetes, this provides direct therapeutic benefit beyond weight loss and is the mechanism that underpins the diabetes approvals.

Reward pathway modulation

GLP-1 receptors in the nucleus accumbens and ventral tegmental area appear to reduce the dopaminergic reward response to calorie-dense foods and potentially other reinforcing stimuli (alcohol, nicotine). Many patients spontaneously reduce alcohol intake and report decreased interest in highly processed foods—even before significant weight loss occurs.

Tirzepatide adds a fifth mechanism through GIP receptor co-agonism. Glucose-dependent insulinotropic polypeptide (GIP) works alongside GLP-1 in energy metabolism; dual activation of both receptor types appears to produce additive or synergistic effects on adiposity. This is the most likely explanation for tirzepatide's greater average weight loss versus semaglutide monotherapy. For a detailed comparison, see our semaglutide vs tirzepatide guide.

All Available GLP-1 Medications in 2026

The GLP-1 class now spans multiple molecules, delivery formats, and FDA indications. Here is every option available to patients as of April 2026:

Molecule	Brand Names	Mechanism	Dosing	Avg Weight Loss	FDA Approval
Liraglutide	Saxenda (weight), Victoza (T2D)	GLP-1 agonist	Daily injection	~8%	2014 (weight, 2010 T2D)
Semaglutide (injectable)	Wegovy (weight), Ozempic (T2D)	GLP-1 agonist	Weekly injection	~15%	2021 (weight, 2017 T2D)
Semaglutide (oral)	Rybelsus	GLP-1 agonist	Daily tablet	~5–10%	2019 (T2D only)
Tirzepatide	Zepbound (weight), Mounjaro (T2D)	Dual GLP-1/GIP agonist	Weekly injection	~20–22%	2023 (weight, 2022 T2D)
Exenatide	Byetta, Bydureon	GLP-1 agonist	Twice daily or weekly	~3–5%	2005 (T2D)

Semaglutide: Ozempic & Wegovy

Semaglutide is a modified GLP-1 analog developed by Novo Nordisk with a half-life of approximately one week, enabling once-weekly subcutaneous injection. Two brand-name formulations are available: Ozempic (approved for type 2 diabetes, max 2.0 mg) and Wegovy (approved for chronic weight management, max 2.4 mg). Although the same molecule, Wegovy uses a higher maintenance dose and a longer titration schedule designed for weight management.

The landmark STEP 1 trial (Wilding et al., NEJM 2021) enrolled 1,961 adults with obesity or overweight and showed that semaglutide 2.4 mg produced a mean 14.9% reduction in body weight versus 2.4% with placebo over 68 weeks. Among participants who reached the maximum dose, average weight loss was 17.4%. The SELECT trial (Lincoff et al., NEJM 2023) further demonstrated that semaglutide reduced major adverse cardiovascular events by 20% in patients with established cardiovascular disease and obesity but without diabetes—marking the first time any obesity medication showed cardiovascular mortality benefit.

Compounded semaglutide is also available through FDA-registered 503B pharmacies and telehealth platforms at a fraction of brand-name cost. Trimi offers compounded semaglutide at $99/month, including provider consultations and ongoing support. For a full cost breakdown, see our GLP-1 cost guide.

Tirzepatide: Mounjaro & Zepbound

Tirzepatide (Eli Lilly) is a single peptide molecule that simultaneously activates both GLP-1 and GIP receptors—a mechanism Lilly calls a "twincretin." Mounjaro was approved for type 2 diabetes in May 2022, and Zepbound received FDA approval for chronic weight management in November 2023. Doses range from 2.5 mg to 15 mg, titrated every four weeks.

The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) showed that tirzepatide 15 mg produced a mean 20.9% reduction in body weight over 72 weeks—with 37.8% of participants losing 25% or more of their body weight. These results are unprecedented for a pharmacological agent and approach outcomes seen with sleeve gastrectomy. The SURMOUNT-4 withdrawal trial confirmed that patients who stopped tirzepatide regained approximately two-thirds of lost weight within a year, reinforcing the chronic-disease framing of obesity treatment.

For a side-by-side clinical comparison with semaglutide, including which patients tend to do better on each medication, see our tirzepatide vs semaglutide comparison.

Liraglutide: Saxenda & Victoza

Liraglutide is a first-generation GLP-1 agonist requiring daily subcutaneous injection. Victoza is approved for type 2 diabetes; Saxenda at the higher dose of 3.0 mg is approved for weight management. The SCALE Obesity trial (Pi-Sunyer et al., NEJM 2015) showed average 8.4% body weight loss over 56 weeks versus 2.8% with placebo.

While less effective than semaglutide or tirzepatide, liraglutide was the first GLP-1 approved specifically for weight loss and paved the way for the current generation. It remains an option for patients who cannot tolerate weekly injections or who have specific clinical considerations. However, most prescribers now favor semaglutide or tirzepatide for new starts due to superior efficacy and once-weekly dosing convenience.

Compounded vs Brand-Name GLP-1 Medications

One of the most common questions patients have in 2026 is whether compounded GLP-1 medications are a legitimate alternative to brand-name drugs. The answer requires understanding how compounding pharmacies operate within the U.S. regulatory framework.

Factor	Brand-Name (Wegovy / Zepbound)	Compounded (503B Pharmacy)
FDA Approval	Yes — full NDA approval	No — compounded products are not FDA-approved
Active Ingredient	Semaglutide / tirzepatide base salt	Semaglutide / tirzepatide base or acetate salt
Manufacturing Oversight	FDA-inspected, cGMP facilities	FDA-registered 503B outsourcing facility or 503A pharmacy
Clinical Trial Data	Extensive (STEP, SURMOUNT trials)	None specific to compounded product
Monthly Cost	$1,000–$1,400 without insurance	$99–$350 through telehealth platforms
Insurance Coverage	Possible with PA; varies by plan	Generally not covered
Supply Reliability	Improved as of 2025–2026	Depends on pharmacy capacity

Compounded GLP-1 medications became widely available when the FDA placed semaglutide and tirzepatide on its drug shortage list, permitting licensed compounding pharmacies to produce these medications. Patients should use only 503B outsourcing facilities or licensed 503A pharmacies with independently verified quality testing. Trimi partners exclusively with FDA-registered 503B facilities. For a complete analysis, read our compounded vs brand-name GLP-1 guide.

Patients who can access brand-name medications at low cost through insurance or manufacturer savings programs should generally prefer FDA-approved products. For patients paying out-of-pocket, compounded versions from reputable pharmacies offer the same active molecule at dramatically lower cost. The clinical decision should be made in partnership with a licensed healthcare provider.

Clinical Trial Results: What the Data Shows

GLP-1 medications have been evaluated in some of the largest randomized controlled trials ever conducted in obesity medicine. The following summarizes key findings:

STEP 1 (Semaglutide)Wilding et al., NEJM 2021

Drug: Semaglutide 2.4 mg weekly

Duration: 68 weeks

Key result: Mean −14.9% body weight vs −2.4% placebo. 50% of patients lost ≥15% body weight.

SELECT (Semaglutide — cardiovascular)Lincoff et al., NEJM 2023

Drug: Semaglutide 2.4 mg weekly

Duration: ~34 months (median)

Key result: 20% reduction in MACE (CV death, non-fatal MI, non-fatal stroke) vs placebo in patients with obesity + established CVD.

SURMOUNT-1 (Tirzepatide)Jastreboff et al., NEJM 2022

Drug: Tirzepatide 5/10/15 mg weekly

Duration: 72 weeks

Key result: Mean −15%, −19.5%, −20.9% body weight at respective doses. 37.8% of 15 mg group lost ≥25% of body weight.

SCALE (Liraglutide)Pi-Sunyer et al., NEJM 2015

Drug: Liraglutide 3.0 mg daily

Duration: 56 weeks

Key result: Mean −8.4% body weight vs −2.8% placebo. 63.2% of patients lost ≥5% of body weight.

These trials all required participants to follow a reduced-calorie diet and engage in increased physical activity, so real-world outcomes may be modestly lower in patients who do not make lifestyle changes. However, patients who combine GLP-1 therapy with dedicated nutrition support often achieve results at or above trial averages. Trimi's program includes evidence-based nutrition guidance as part of every membership.

GLP-1 Side Effects: What to Expect and How to Manage Them

Gastrointestinal side effects are the most common reason patients discontinue GLP-1 therapy prematurely—and the most preventable with the right approach. Here is the complete picture:

Common Side Effects (by frequency)

Nausea: 20–44% of patients; highest during dose escalation; usually improves within 4–8 weeks of a new dose
Diarrhea: 21–30%; often transient around dose changes
Vomiting: 9–24%; triggered by large or fatty meals
Constipation: 11–24%; increase fiber and fluid intake
Abdominal discomfort / bloating: 10–15%
Fatigue: 10–15%; often related to reduced caloric intake
Injection site reactions: 5–10%; rotate sites
Headache: 5–10%; dehydration often a contributing factor

Evidence-Based Management Strategies

• Eat slowly, in small portions; stop at first satiety signal
• Avoid fried, fatty, and spicy foods during dose increases
• Stay well-hydrated (64–80 oz water daily)
• Follow the prescribed 4-week titration schedule; don't rush
• Take the injection after a meal if nausea is severe
• Ginger tea, B6, or OTC anti-nausea agents for acute nausea
• Increase dietary fiber and consider a fiber supplement for constipation
• Ensure adequate protein (0.7–1.0g/lb of goal body weight) to prevent muscle loss

Serious but Rare Adverse Events

Pancreatitis: Reported in <1% of patients. Seek immediate care for severe, persistent upper abdominal pain radiating to the back.

Gallbladder disease: Cholelithiasis (gallstones) occurs in ~1.5–2.4% of patients, attributed to rapid weight loss rather than the drug directly.

Thyroid C-cell tumors: Observed in rodent studies; relevance in humans is uncertain. Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2.

Acute kidney injury: Rare; associated with severe dehydration from GI side effects. Stay hydrated and contact your provider if unable to keep fluids down.

For a comprehensive side-effect management resource, including medication-specific strategies for semaglutide versus tirzepatide, see our complete side effects guide.

Who Qualifies for GLP-1 Weight Loss Treatment?

FDA-Approved Eligibility Criteria

BMI ≥ 30 (obesity)

Qualifies regardless of other health conditions

BMI ≥ 27 (overweight) + at least one:

• Type 2 diabetes or prediabetes
• Hypertension (high blood pressure)
• Dyslipidemia (high cholesterol / triglycerides)
• Obstructive sleep apnea
• Cardiovascular disease
• Osteoarthritis related to weight

Applies to Wegovy (semaglutide) and Zepbound (tirzepatide) for weight management

Contraindications

Absolute (do not use):

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia type 2 (MEN 2)
• Pregnancy (stop ≥2 months before conception attempt)

Relative (discuss with provider):

• History of pancreatitis
• Active gallbladder disease
• Severe chronic kidney disease (eGFR <30)
• History of eating disorders
• Narrow-therapeutic-index drug interactions

Use our GLP-1 eligibility assessment to evaluate your specific situation, or see BMI requirements for weight loss medications for a detailed breakdown of criteria.

GLP-1 Cost Landscape in 2026

Cost remains the most significant barrier to GLP-1 access in the United States. Here is an honest overview of what patients pay across every access pathway:

Brand-name without insurance

$1,000–$1,400 per month for Wegovy or Zepbound. Retail list prices have remained above $1,000/month as of Q1 2026.

Brand-name with insurance

$0–$300 per month for commercially insured patients with prior authorization. Many Medicare Part D plans now cover Zepbound following the Inflation Reduction Act provisions taking effect in 2026.

Manufacturer savings cards

Novo Nordisk's Wegovy savings program and Lilly's Zepbound savings card can reduce out-of-pocket costs to $25–$150/month for eligible commercially insured patients (not valid for government insurance).

Compounded semaglutide (telehealth)

$99–$299 per month all-inclusive through platforms like Trimi ($99/mo), which bundle the medication, provider consultation, and ongoing medical support.

Compounded tirzepatide (telehealth)

$125–$350 per month through compounding-friendly telehealth platforms. Slightly higher than compounded semaglutide due to higher base ingredient cost.

For guidance on navigating insurance prior authorizations, appeals processes, and patient assistance programs, see our tirzepatide insurance coverage guide and how to appeal a GLP-1 insurance denial.

How to Get Started with GLP-1 Treatment

Patients have three main pathways to access GLP-1 medications. Here is an honest comparison:

Primary Care / Specialist

1. Schedule appointment (2–8 weeks wait)
2. In-person evaluation and lab work
3. Prescription written if eligible
4. Work with insurance/pharmacy

Timeline: 3–6 weeks to first dose

Cost: Varies; insurance copays

Best for patients with complex medical histories

Traditional Telehealth

1. Complete online intake form
2. Async or live video consult
3. Prescription to retail pharmacy
4. Patient sources medication

Timeline: 5–14 days to first dose

Cost: Consult fee + pharmacy cost

Good if you have insurance coverage

Trimi — $99/mo

1. Complete health questionnaire (10 min)
2. Licensed provider review (same day)
3. Prescription written if eligible
4. Medication shipped to your door

Timeline: 3–5 days to first dose

Cost: $99/month all-inclusive

Lowest cost path; compounded semaglutide included

Start with Trimi at $99/Month

Trimi is the most affordable path to compounded semaglutide. Complete your health intake today and a licensed provider will review your case—most patients receive a decision the same day. Medication ships directly to you, with ongoing provider support included.

Get Started Today

For a step-by-step walkthrough of the intake and titration process, see our how to start semaglutide guide and what to expect your first month.

Emerging GLP-1 Medications: The Pipeline

The next generation of GLP-1 and related metabolic medications is advancing rapidly through clinical trials. These agents may redefine what is achievable with pharmacotherapy for obesity:

Retatrutide (LY3437943)

Phase 3 trials ongoing

Eli Lilly · Triple agonist: GLP-1 + GIP + glucagon receptors

Phase 2 data showed mean 24.2% body weight loss at 48 weeks—the highest ever reported for any pharmacological agent. The glucagon agonism component may accelerate fat burning beyond what GLP-1/GIP dual agonism achieves. FDA approval expected 2026–2027 pending Phase 3 results.

Orforglipron (LY3502970)

Phase 3 trials (ACHIEVE program)

Eli Lilly · Oral non-peptide GLP-1 receptor agonist (small molecule)

Phase 2 showed ~14.7% body weight loss over 36 weeks—comparable to injectable semaglutide. Unlike peptide-based GLP-1s, orforglipron is a small molecule taken as a daily oral tablet, eliminating the need for injections. This could dramatically expand access for patients with injection anxiety.

CagriSema

Phase 3 (REDEFINE program)

Novo Nordisk · Combination: semaglutide + cagrilintide (amylin analog)

Combines GLP-1 receptor agonism with amylin receptor agonism. Phase 2 data from SCALE-DUAL showed 15.6% weight loss vs 8.8% for semaglutide alone at 32 weeks. Phase 3 results are anticipated in 2025–2026.

Mazdutide / Pemvidutide / Survodutide

Phase 2–3

Various (Innovent, Altimmune, Boehringer Ingelheim) · GLP-1/glucagon dual agonists (various)

Multiple GLP-1/glucagon dual agonists are in mid-to-late stage trials, with early data suggesting strong weight loss and potential liver disease (MASH) benefits. These agents add glucagon's thermogenic and hepatic effects to GLP-1's appetite suppression.

The next 3–5 years are likely to bring oral GLP-1 options, triple-agonist agents with greater than 25% weight loss potential, and expanded indications spanning cardiovascular disease, kidney disease, and metabolic-associated steatohepatitis (MASH). See our 2026 GLP-1 pipeline analysis for the full forecast.

Frequently Asked Questions

What is GLP-1 and how do GLP-1 medications work for weight loss?

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after eating. GLP-1 receptor agonist medications mimic this hormone at pharmacological concentrations, suppressing appetite in the brain, slowing gastric emptying, and regulating blood sugar. The result is a sustained reduction in caloric intake that produces 15–22% body weight loss in clinical trials.

What is the difference between semaglutide and tirzepatide?

Semaglutide (Wegovy, Ozempic) activates only GLP-1 receptors and produces average 15% body weight loss. Tirzepatide (Mounjaro, Zepbound) is a dual agonist targeting both GLP-1 and GIP receptors, producing average 20–22% body weight loss. Both are once-weekly injections. Tirzepatide generally produces more weight loss; semaglutide has a longer safety record.

Who qualifies for GLP-1 weight loss medications?

FDA-approved criteria: adults with BMI ≥ 30 (obesity), or BMI ≥ 27 (overweight) with at least one weight-related condition such as type 2 diabetes, hypertension, high cholesterol, or sleep apnea. Absolute contraindications include personal or family history of medullary thyroid cancer or MEN 2 syndrome.

What are the most common side effects of GLP-1 medications?

The most common side effects are gastrointestinal: nausea (20–44%), diarrhea (21–30%), vomiting (9–24%), and constipation (11–24%). These peak during dose escalation and improve over weeks. Eating smaller meals, staying hydrated, and following the titration schedule minimize discomfort. Serious adverse events—pancreatitis, gallbladder disease—are rare.

What is the difference between compounded and brand-name GLP-1 medications?

Brand-name medications (Wegovy, Zepbound) are FDA-approved with full clinical-trial safety data and manufacturing standards. Compounded versions are made by licensed 503B or 503A pharmacies and are not FDA-approved, but are significantly cheaper. Quality varies by pharmacy. Trimi sources compounded semaglutide from FDA-registered facilities at $99/month.

How much do GLP-1 medications cost without insurance?

Brand-name Wegovy and Zepbound cost $1,000–$1,400/month without insurance. Compounded semaglutide through telehealth platforms runs $99–$299/month. Compounded tirzepatide is typically $125–$350/month. Manufacturer savings cards can reduce brand-name costs to $25–$150/month for eligible commercially insured patients.

What is retatrutide and when will it be available?

Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors in development by Eli Lilly. Phase 2 trials showed up to 24.2% body weight loss at 48 weeks—more than any currently approved medication. Phase 3 trials are ongoing; FDA approval is expected no earlier than 2026–2027.

Sources & References

Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021;384:989–1002.
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022;387:205–216.
Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM. 2023;389:2221–2232.
Pi-Sunyer X, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). NEJM. 2015;373:11–22.
Jastreboff AM, et al. Triple Hormone Receptor Agonist Retatrutide for Obesity. NEJM. 2023;389:514–526.
Dahl D, et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Adults with Type 2 Diabetes. JAMA. 2022;327:534–545.
FDA Prescribing Information: Wegovy (semaglutide injection) 2.4 mg. Novo Nordisk. 2024.
FDA Prescribing Information: Zepbound (tirzepatide injection). Eli Lilly. 2023.
FDA Prescribing Information: Saxenda (liraglutide injection) 3 mg. Novo Nordisk. 2023.
Obesity Medicine Association. Clinical Practice Statement on Obesity Pharmacotherapy. 2024.
American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1).
Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). NEJM. 2016;375:1834–1844.

Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. GLP-1 medications are prescription drugs that require evaluation by a licensed healthcare provider. Information reflects clinical trial data and prescribing information available as of April 2026 and is subject to change. Individual results vary. Do not start, stop, or modify any prescription medication without professional guidance. Always consult a qualified healthcare provider about your specific medical situation.

What This Guide Covers